• Efficacy of Respibron for the Immunoprophylaxis of Chronic and Recurrent Rhinosinusitis in Children

Efficacy of Respibron for the Immunoprophylaxis of Chronic and Recurrent Rhinosinusitis in Children

SOVREMENNAYA PEDIATRIYA.2017.4(84):22-28; doi 10.15574/SP.2017.84.22

Pysanko V. M.
SI «Kolomiychenko Institute of Otolaryngology of NAMS of Ukraine», Kyiv

Objective — to evaluate the efficacy of Respibron usage in children with chronic or recurrent rhinosinusitis and administration of mucosal vaccine in the complex treatment in children.

Materials and methods. A total of 60 children aged 6 to 17 years who treated in the previous stage. Children of the 1st group were administrated Respibron with the purpose of immunoprophylaxis, and the 2st group were assigned a combination of Respibron and Echinacea. The children of the control group were not administrated placebo, and the immune parameters of these patients served to assess the changes of immune response in patients of the main group under the influence of immunomodulators. During the follow-up examination in one, three and six months after the completed immunoprophylaxis, children were undergoing a standard otolaryngologic inspection and endoscopic examination of nasal cavity, evaluation of the immune system state.

Results. Immunoprophylaxis of rhinosinusitis with Respibron was effective in 70% of patients. The combination of phytoimmunomodulator (Echinacea), which stimulates proliferation and differentiation of immunocompetent cells, and mucosal vaccine (Respibron), provided a positive effect in 95% of the examined patients.

Conclusions The high efficacy of Respibron for prevention of exacerbations and recurrence of rhinosinusitis in children was proved. The immunoprophylactic effects of Respibron is significantly enhanced while combined with the immunomodulator.

Key words: rhinosinusitis, children, immunoprophylaxis, mucosal vaccine.

References

1. Aryaev NL, Tsiunchik YuG. (2006). O neobhodimosti nekotoryih terminologicheskih utochneniy v pediatrii. Sovremennaya pediatriya. 1(10): 14—17.

2. Baleva LS, Korovina MP. (2006). Sovremennyie podhodyi k lecheniyu i reabilitatsii chasto boleyuschih detey. Agentstvo meditsinskogo marketinga. Moskva, Agentstvo meditsinskogo marketinga: 53.

3. Drannik GN, Kurchenko AI, Drannik AG. (2009). Immunnaya sistema slizistyih, fiziologicheskaya mikroflora i probiotiki. Kiev, Poligraf plyus: 143.

4. Kozlov VS, Shilenkova VV, Shilenkov AA. (2003). Sinusityi: sovremennyiy vzglyad na problemu. Consilium medicum. 5; 4: 20—24.

5. Pysanko VM et al. (2014). Mozhlyvosti imunoprofilaktyky rynosynusytiv u ditei. Povidomlennia 1. Osoblyvosti imunnykh porushen u ditei z khronichnymy ta retsydyvuiuchymy rynosynusytamy. Rynolohiia. 1: 23—30.

6. Osnovyi vaktsinoprofilaktiki u detey s hronicheskoy patologiey. Pod red MP Kostinova. (2002). Moskva: 320.

7. Simovyan EN, Denisenko MV, Grigoryan AV. (2007). Chasto boleyuschie deti: optimizatsiya programmyi lecheniya. Pediatriya. 4: 79—85.

8. Kovtun TA, Usenko DV, Tutelyan AV, Shabalina SV. (2012). Sovremennaya terapiya ostryih respiratornyih zabolevaniy u detey. Infektsionnyie bolezni. 1: 74-79.

9. Carredu F. (1994). Role of immunoactivation with pidotimodin recurrent respiratory infection in pediatric patients. Arzneimittel-Forschung. 44; 12A: 1506—1511.

10. Graham MH. (1990). The epidemiology of acute respiratory infections in children and adults. Epidemiology Rev. 120; 2: 149—178. https://doi.org/10.1093/oxfordjournals.epirev.a036050

11. Hassan H Ramadan. (2017, Jan 25). Medical Treatment of Pediatric Sinusitis. Otolaryngology and Facial Plastic Surgery.

12. Jartti T, Lee WM, Pappas T et al. (2008). Serial viral infections in infants with recurrent respiratory illnesses. European Respiratory Journal. 32; 2: 314—320. https://doi.org/10.1183/09031936.00161907; PMid:18448489 PMCid:PMC2843696

13. Wald ER. (1992). Sinusitis in infant and children. Ann Otol Rhinol Laryngol. 155; 1: 37—41. https://doi.org/10.1177/00034894921010S108

Содержание журнала Full text of article